Login to Your Account

Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma

By Cormac Sheridan

Wednesday, August 27, 2008
Novosom AG in-licensed from Isis Pharmaceuticals Inc. the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ transplant rejection. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription